跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 116,578 条关于
“HR+/HER2- early breast cancer”
全部
116,578
临床试验
90,654
药物
2,667
机构
1,203
资讯
22,054
2年前
Kisqali Demonstrates Sustained Benefit in HR+/HER2- Early Breast Cancer
去年
FDA Approves Ribociclib for Early HR+/HER2- Breast Cancer Based on NATALEE Trial Results
2年前
De-escalated Therapy Shows Excellent Survival in HR+/HER2+ Breast Cancer
2年前
Kisqali Plus Endocrine Therapy Reduces Breast Cancer Recurrence by 28.5% in Phase 3 Trial
去年
Lilly's Verzenio Demonstrates Significant Overall Survival Benefit in High-Risk Early Breast Cancer
去年
Adjuvant Ribociclib Approved for HR+/HER2- Early Breast Cancer, Offering New Hope for High-Risk Patients
2年前
Kisqali Demonstrates Sustained Benefit in Early Breast Cancer
2年前
Kisqali Deepens Benefit in Early Breast Cancer, Reducing Recurrence Risk by 28.5%
2年前
Kisqali Shows Enhanced Efficacy in Younger Breast Cancer Patients with 33% Risk Reduction
2年前
Novartis Highlights New Data on Kisqali, Iptacopan, and Scemblix at SABCS and ASH
第 1 页，共 2206 页
上一页
下一页
